Impact of the Surgical Approach for Neoadjuvantly Treated Gastroesophageal Junction Type II Tumors-Reference-Cited by-同舟云学术

Impact of the Surgical Approach for Neoadjuvantly Treated Gastroesophageal Junction Type II Tumors

Published:2023-07-31 Issue:5 Volume:278 Page:683-691
ISSN:0003-4932
Container-title:Annals of Surgery
language:en
Short-container-title:

Author:

Wirsik Naita M.¹,Schmidt Thomas¹,Nienhüser Henrik²,Donlon Noel E.³⁴,de Jongh Cas⁵,Uzun Eren⁶,Fuchs Hans F.¹,Brunner Stefanie¹,Alakus Hakan¹,Hölscher Arnulf H.⁷,Grimminger Peter⁶,Schneider Martin²,Reynolds John V.³⁴,van Hillegersberg Richard⁵,Bruns Christiane J.¹

Affiliation:

1. Department of General, Visceral, Cancer, and Transplant Surgery, University Hospital of Cologne, Cologne, Germany

2. Department of General, Visceral, and Transplant Surgery, University Hospital of Heidelberg, Heidelberg, Germany

3. Department of Surgery, School of Medicine, Trinity College Dublin, Dublin, Ireland

4. Trinity St James’ Cancer Institute, St James’s Hospital Dublin, Dublin, Ireland

5. Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

6. Department of General, Visceral, and Transplant Surgery, University Medical Center of the Johannes Gutenberg University, Mainz, Germany

7. Contilia Center for Esophageal Diseases, Elisabeth Hospital Essen, Essen, Germany

Abstract

Objective: The aim of this study was to explore oncologic outcomes of transhiatal gastrectomy (THG) or transthoracic esophagectomy (TTE) for neoadjuvantly treated gastroesophageal junction (GEJ) Siewert type II adenocarcinomas, a multinational, high-volume center cohort analysis was undertaken. Background: Neoadjuvant radiochemotherapy or perioperative chemotherapy (CTx) followed by surgery is the standard therapy for locally advanced GEJ. However, the optimal surgical approach for type II GEJ tumors remains unclear, as the decision is mainly based on individual experience and assessment of operative risk. Methods: A retrospective analysis of 5 prospectively maintained databases was conducted. Between 2012 and 2021, 800 patients fulfilled inclusion criteria for type II GEJ tumors and neoadjuvant radiochemotherapy or CTx. The primary endpoint was median overall survival (mOS). Propensity score matching was performed to minimize selection bias. Results: Patients undergoing THG (n=163, 20.4%) had higher American Society of Anesthesiologists (ASA) classification and cT stage (P<0.001) than patients undergoing TTE (n=637, 79.6%). Neoadjuvant therapy was different as the THG group were mainly undergoing CTx (87.1%, P<0.001). The TTE group showed higher tumor regression (P=0.009), lower ypT/ypM categories (both P<0.001), higher nodal yield (P=0.009) and higher R0 resection rate (P=0.001). The mOS after TTE was longer (78.0 vs 40.0 months, P=0.013). After propensity score matching a higher R0 resection rate (P=0.004) and mOS benefit after TTE remained (P=0.04). Subgroup analyses of patients without distant metastasis (P=0.037) and patients only after neoadjuvant chemotherapy (P=0.021) confirmed the survival benefit of TTE. TTE was an independent predictor of longer survival. Conclusion: Awaiting results of the randomized CARDIA trial, TTE should in high-volume centers be considered the preferred approach due to favorable oncologic outcomes.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Surgery

Reference40 articles.

1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries;Botterweck;Int J Epidemiol,2000

3. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment;DeMeester;Ann Surg Oncol,2006

4. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma;Lagergren;N Engl J Med,1999

5. Preoperative chemoradiotherapy for esophageal or junctional cancer;van Hagen;N Engl J Med,2012